- Poster presentation
- Open Access
PB.45: Evaluation of a pilot MRI breast surveillance project for young women at high risk of breast cancer
© De Souza et al.; licensee BioMed Central Ltd. 2013
- Published: 8 November 2013
- Breast Cancer
- BRCA2 Mutation
- Digital Mammography
- TP53 Gene
- Qualitative Feedback
NICE Clinical Guidelines recommend that young women at high risk of breast cancer are offered annual surveillance with MRI and digital mammography. A feasibility study was run over 3 years (2010 to 2013) for women with known BRCA1 or BRCA2 mutations and those with, or at high risk of, a TP53 gene mutation. We aimed to explore the practicalities of delivering a surveillance service for these high-risk women.
Eligible women were identified by the All-Wales Medical Genetics Service and offered annual MRI, with digital mammography where appropriate, at three centres across Wales. Administration was managed by Breast Test Wales.
Qualitative feedback showed that women were willing to travel for appointments and the service was acceptable. Only 12 of the 38 participants attended all years. This is a dynamic group - some develop cancer, others opt for risk-reducing surgery, and each year some were ineligible as they were pregnant or breastfeeding. Administration of the system was complex, involving different professional groups working across sites. Standards for waiting times for results were not met. Few radiologists in Wales meet the English standard of 100 breast MRI examinations per year to be eligible as readers. This poses a challenge for service delivery. MRI scanner capacity is also limited.
The enthusiasm of the multidisciplinary team ensured the project was successful and the service delivered. However, there were major administrative and resource challenges, and the pilot service model was unsustainable. The evaluation will be used to inform decisions on future service provision.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.